A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 997-1005

  Thornton, K A ^a   Chen, A R ^a   Trucco, M M ^a,b   Shah, P ^a   Wilky, B A ^a   Gul, N ^a   Carrera Haro, M A ^a   Ferreira, M Fogle ^a   Shafique, U ^a   Powell, J D ^a   Meyer, C F ^a   Loeb, D M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cancer stem cell; chemoresistance; clinical trial; mTOR; sarcoma

Indexed keywords

ALDEHYDE DEHYDROGENASE; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; RAPAMYCIN; RIDAFOROLIMUS; TEMOZOLOMIDE; TEMSIROLIMUS; TRABECTEDIN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BLOOD TOXICITY; CHILD; CHONDROSARCOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CRYOABLATION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DOSE CALCULATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EVENT FREE SURVIVAL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; STOMATITIS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SARCOMA; SIROLIMUS; YOUNG ADULT;

EID: 84878885068     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28083     Document Type: Article

References (12)

1. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44. (Pubitemid 44623625)
2. Rasheed ZA, Kowalski J, Smith BD, et al. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-7.
3. Awad O, Yustein JT, Shah P, et al. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 2010; 5: e13943.
4. Muggia FM,. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997; 54 (Suppl 4): 22-9. (Pubitemid 27487792)
5. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 78-84.
6. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 2011; 117: 3468-75.
7. Garrett-Mayer E,. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials 2006; 3: 57-71.
8. Piantadosi S, Fisher JD, Grossman S,. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 1998; 41: 429-36. (Pubitemid 28140705)
9. Goodman SN, Zahurak ML, Piantadosi S,. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-61.
10. O'Quigley J, Pepe M, Fisher L,. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46: 33-48. (Pubitemid 20245604)
11. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37: 870-7. (Pubitemid 32323965)
12. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.